 Antineoplastic Combined Chemotherapy Protocols
"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
| Descriptor ID |
D000971
|
| MeSH Number(s) |
E02.183.750.500 E02.319.077.500 E02.319.310.037
|
| Concept/Terms |
Antineoplastic Combined Chemotherapy Protocols- Antineoplastic Combined Chemotherapy Protocols
- Combined Antineoplastic Agents
- Antineoplastic Agents, Combined
- Agent, Combined Antineoplastic
- Agents, Combined Antineoplastic
- Antineoplastic Agent, Combined
- Combined Antineoplastic Agent
- Antineoplastic Combined Chemotherapy Regimens
- Drug Combinations, Antineoplastic
- Anticancer Drug Combinations
- Anticancer Drug Combination
- Drug Combination, Anticancer
- Drug Combinations, Anticancer
- Antineoplastic Drug Combinations
- Antineoplastic Drug Combination
- Combinations, Antineoplastic Drug
- Drug Combination, Antineoplastic
Antineoplastic Chemotherapy Protocols- Antineoplastic Chemotherapy Protocols
- Antineoplastic Chemotherapy Protocol
- Chemotherapy Protocol, Antineoplastic
- Protocol, Antineoplastic Chemotherapy
- Protocols, Antineoplastic Chemotherapy
- Cancer Chemotherapy Protocols
- Cancer Chemotherapy Protocol
- Chemotherapy Protocol, Cancer
- Chemotherapy Protocols, Cancer
- Protocol, Cancer Chemotherapy
- Protocols, Cancer Chemotherapy
- Chemotherapy Protocols, Antineoplastic
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in this website by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 9 | 2 | 11 | | 1997 | 10 | 2 | 12 | | 1998 | 15 | 1 | 16 | | 1999 | 5 | 2 | 7 | | 2000 | 7 | 1 | 8 | | 2001 | 15 | 1 | 16 | | 2002 | 8 | 4 | 12 | | 2003 | 8 | 8 | 16 | | 2004 | 15 | 5 | 20 | | 2005 | 9 | 7 | 16 | | 2006 | 21 | 8 | 29 | | 2007 | 17 | 6 | 23 | | 2008 | 23 | 11 | 34 | | 2009 | 14 | 8 | 22 | | 2010 | 21 | 14 | 35 | | 2011 | 28 | 10 | 38 | | 2012 | 23 | 10 | 33 | | 2013 | 30 | 14 | 44 | | 2014 | 39 | 17 | 56 | | 2015 | 36 | 19 | 55 | | 2016 | 40 | 23 | 63 | | 2017 | 39 | 21 | 60 | | 2018 | 49 | 20 | 69 | | 2019 | 52 | 25 | 77 | | 2020 | 53 | 21 | 74 | | 2021 | 38 | 34 | 72 | | 2022 | 9 | 53 | 62 | | 2023 | 1 | 68 | 69 | | 2024 | 43 | 37 | 80 | | 2025 | 64 | 11 | 75 | | 2026 | 19 | 3 | 22 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
Smith AA, Onar-Thomas A, Lensing S, Dalton J, Bennett J, Tatevossian RG, Bertrand K, Lindsay H, Tabori U, Owens-Pickle E, Blackburn PR, Handler MH, Chambwe N, El Khoury L, Lau C, Kunin-Batson A, Sands S, Wu S, Zhou T, Chang A, Merchant TE, Leary S, Fouladi M, Gajjar A, Pollack IF, Foreman NK, Ellison DW. Phase 3 randomized trial of postirradiation chemotherapy in patients with newly diagnosed ependymoma: A report from the Children's Oncology Group. Neuro Oncol. 2026 May 01; 28(5):1286-1297.
-
Peng C, Catalano P, Zalcberg J, Thor AD, Weiner LM, Khandekar JD, Cohen D, Weinshel EL, O'Dwyer PJ, Benson AB. ECOG-ACRIN E6293: Phase II Study of Raltitrexed in Advanced Colorectal Cancer. Oncologist. 2026 Apr 10; 31(5).
-
Abramson JS, Straus DJ, Bartlett NL, Burke JM, Lynch RC, Domingo Domenech E, Hess B, Schuster SR, Linhares Y, Gandhi M, Shah HR, Jurczak W, Re A, Hahn U, Prince HM, Guo W, Davis G, Ho L, Fanale M, Yasenchak CA, Lee HJ. Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma. Blood. 2026 Apr 09; 147(15):1713-1722.
-
Zheng DJ, Hettinger G, Aftandilian C, Bona K, Caywood EH, Collier AB, Elgarten CW, Gathers C, Ghosh T, Gramatges MM, Henry M, Huang YV, Li Y, Lotterman C, Maloney K, Mian A, Miller TP, Modi A, Mody R, Morgan E, Myers R, Newman H, Ortiz J, Seif AE, Smith C, Stokke J, Wang X, Winick N, Wilkes JJ, Wong V, Aplenc R, Getz KD. Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort. J Natl Cancer Inst. 2026 Apr 01; 118(4):746-750.
-
Maruzzo M, Poprach A, Buti S, Bamias A, Zakopoulou R, DE Giorgi U, Kucharz J, Formisano L, Buttner T, Zucali PA, Li H, Incorvaia L, Kopp RM, Messina C, Kopecky J, Fornarini G, Landmesser J, Rebuzzi SE, Nasso C, Fay AP, Bhuva D, Pinto A, Buchler T, Pichler R, Kanesvaran R, Soares A, Massari F, Monteiro FS, Dos Santos Filho IA, Porta C, Basso U, Santoni M. Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study). Minerva Urol Nephrol. 2026 Apr; 78(2):210-221.
-
Hinz TK, Le AT, Doan T, Ast A, Jaramillo S, Avila JT, Skhisov D, Haines S, Navarro AC, Patil T, Nemenoff RA, Heasley LE. Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma. Cancer Lett. 2026 Jun 28; 648:218467.
-
Sinicrope FA, Ou FS, Arnold D, Peters WR, Behrens RJ, Lieu CH, Matin K, Cohen DJ, Potter SL, Nixon AB, Kottschade LA, Kathol E, Frankel WL, Shergill A, Hsu D, Reinacher-Schick A, Mehan P, Gold PJ, Khalil MF, Zemla T, Gatten C, O'Reilly EM, Meyerhardt JA. Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2026 Mar 26; 394(12):1155-1166.
-
Mollica V, Massari F, Fujita K, Giannatempo P, Grande E, Büttner T, Bourlon MT, Taha T, Fukuokaya W, Myint ZW, Pichler R, Binz K, Molina-Cerrillo J, Kopecky J, de Liaño AG, Kucharz J, Fiala O, Matrana MR, Kopp RM, Di Civita MA, Zgura A, Ansari J, Kihnel R, De Felice F, Angel M, Monteiro FSM, Soares A, Urun Y, Buti S, Santini D, Santoni M. Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV). Cancer Immunol Immunother. 2026 Mar 24; 75(4).
-
Flerlage JE, Feraco AM, Zhou Y, Zheng Y, Liang J, Lucas JT, Friedmann AM, Weinstein HJ, Yock TI, Shulkin B, Kaste SC, Marks LJ, Ehrhardt MJ, Dixon SB, Howard S, de Alarcon P, Luna-Fineman S, Geddis A, Larsen EC, Marcus K, Billett AL, Donaldson SS, Hudson MM, Metzger ML, Krasin MJ, Link MP. Dose-dense chemotherapy enables elimination of RT for the majority of low-risk pediatric Hodgkin lymphomas: PHC study HOD08. Blood. 2026 Mar 19; 147(12):1289-1301.
-
Lerman BJ, King M, Mody R, Onyeama SJ, Marachelian A, Cash T, Federico SM, Granger M, Desai AV, Shusterman S, Foster JH, Sokol E, Greer C, Streby K, Meany HJ, Vo KT, Macy ME, Bagatell R. Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective Study. Pediatr Blood Cancer. 2026 May; 73(5):e70195.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|